Betta Pharmaceuticals Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Joint Venture, Public, Subsidiary
- Established
- 2003-01-07
- Employees
- 1.9K
- Market Cap
- -
- Website
- https://www.bettapharma.com
The Absorption, Metabolism and Excretion of [14C]D-0316 in Human
Phase 1
- Conditions
- Advanced or Metastatic Non-small Cell Lung
- Interventions
- Drug: [14C]D-0316 suspension
- First Posted Date
- 2020-07-09
- Last Posted Date
- 2021-06-02
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 4
- Registration Number
- NCT04464551
- Locations
- 🇨🇳
Jiangsu Province Hospital Affiliated to Nanjing Madical University of Medicine, Nanjing, Jiangsu, China
X-396 (Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases
Phase 2
- Conditions
- Brain MetastasesLung Cancer, Nonsmall Cell
- Interventions
- Drug: X-396(Ensartinib)
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2020-06-04
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 37
- Registration Number
- NCT04415320
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC
Phase 2
Active, not recruiting
- Conditions
- EGFR Gene MutationNon-Small Cell Lung Cancer
- Interventions
- Drug: D-0316 Capsule
- First Posted Date
- 2019-12-20
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 362
- Registration Number
- NCT04206072
- Locations
- 🇨🇳
The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, Zhejiang, China
🇨🇳Liuzhou Workers Hospital, Liuzhou, China
A Study to Determine the Efficiency For Brain Metastasis NSCLC Patients Treated With Icotinib Alone or Combined With Radiation Therapy
Phase 3
- Conditions
- Non Small Cell Lung CancerBrain Metastases
- Interventions
- Radiation: SRS/WBRT/HA-WBRT/SMART
- First Posted Date
- 2019-08-15
- Last Posted Date
- 2019-08-15
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 296
- Registration Number
- NCT04058704
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
The Absorption, Metabolism and Excretion of [14C]Ensartinib in Human
- First Posted Date
- 2019-01-15
- Last Posted Date
- 2019-01-15
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 6
- Registration Number
- NCT03804541
- Locations
- 🇨🇳
Jiangsu Province Hospital Affiliated to Nanjing Madical University of Medicine, Nanjing, Jiangsu Provence, China
A Phase I Study of BPI-16350 in Patients with Advanced Solid Tumor
- First Posted Date
- 2019-01-02
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 54
- Registration Number
- NCT03791112
- Locations
- 🇨🇳
Betta Pharmaceuticals Co., Hangzhou, Zhejiang Provice, China
Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation
Phase 2
- Conditions
- Non-Small Cell Lung CancerBrain Metastases
- Interventions
- Radiation: WBRT or SRS
- First Posted Date
- 2018-11-27
- Last Posted Date
- 2018-11-27
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 162
- Registration Number
- NCT03754530
Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer
- First Posted Date
- 2018-11-21
- Last Posted Date
- 2018-11-21
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT03749213
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Science, Beijing, China
X-396 Capsule in Advanced NSCLC Patients With ROS1 Gene Rearrangement
- First Posted Date
- 2018-07-31
- Last Posted Date
- 2020-01-09
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 69
- Registration Number
- NCT03608007
- Locations
- 🇨🇳
Chest hospital affiliated to Shanghai jiao tong university, Shanghai, Shanghai, China
Bioequivalency Study of Ensartinib Capsules in Healthy Volunteers
Phase 1
Completed
- Conditions
- Lung Cancer
- Interventions
- First Posted Date
- 2018-05-24
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 74
- Registration Number
- NCT03536481
- Locations
- 🇨🇳
Shanghai Public Health Clinical Center, Shanghai, Shanghai, China